Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.67 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.66 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.66 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.66 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.66 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.66 |
| ▸ | RHOC | P08134 | 1/20 | 0.64 |
| ▸ | RHOA | P61586 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4286068 | 0.92 | MAPT (0.94) | P2RX1MAPTLMNAKCNK3PTGS1 | |
| SCHEMBL23304103 | 0.88 | P2RX1 (1.00) | P2RX1MAPTLMNAKCNK3PTGS1 | |
| SCHEMBL30739929 | 0.87 | LMNA (1.00) | P2RX1MAPTLMNAKCNK3PTGS1 | |
| SCHEMBL4517587 | 0.87 | LMNA (1.00) | P2RX1MAPTLMNAKCNK3PTGS1 | |
| SCHEMBL23447713 | 0.87 | P2RX1 (1.00) | P2RX1MAPTLMNAKCNK3RAB9A | |
| SCHEMBL23336404 | 0.86 | P2RX1 (0.76) | P2RX1MAPTLMNAKCNK3MEN1 | |
| SCHEMBL15603515 | 0.85 | MAPT (0.81) | P2RX1MAPTLMNAKCNK3PTGS1 | |
| SCHEMBL20073524 | 0.85 | MAPT (0.81) | P2RX1MAPTLMNAKCNK3PTGS1 | |
| SCHEMBL30739967 | 0.84 | LMNA (0.78) | P2RX1MAPTLMNAKCNK3PTGS1 | |
| SCHEMBL28668959 | 0.84 | LMNA (0.83) | P2RX1MAPTLMNAKCNK3PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1519932-B1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LTD (GB) | 2007-10-03 | — | — | EP | claimed |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CYCLACEL LIMITED (GB) | 2005-09-29 | — | — | US | claimed |
| EP-1519932-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | Cyclacel Limited (GB) | 2005-04-06 | — | — | EP | claimed |
| WO-2004005278-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LIMITED (GB) | 2004-01-15 | — | — | WO | claimed |
| EP-1519932-B1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LTD (GB) | 2007-10-03 | — | — | EP | disclosed |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CYCLACEL LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
| EP-1519932-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | Cyclacel Limited (GB) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004005278-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CCNL2, TP53, MDM2 | P2RX1 3101/4885MAPT 4117/4885LMNA 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.